Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.~* Have difficult to treat sites at presentation.~* Age ≥18 years.~* No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.~Exclusion Criteria:~* Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.~* Previous use of another biological treatment for treatment of moderate-to-severe PsO.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with moderate to severe plaque psoriasis (Type: None): Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease

Based on this trial design, predict the completion outcome and termination type (if applicable).